Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × relatlimab × Gastrointestinal × Clear all

Phase

Phase 2 8 Phase 1 3 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2 Dermatologic 2 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Gynecologic 1 Gastrointestinal 1

Conditions

Gastroesophageal Cancer 1

Interventions

Gemcitabine 131 Oxaliplatin 106 Fluorouracil 94 Capecitabine 92 pembrolizumab 82 Bevacizumab 69 Nivolumab 65 Leucovorin 65 Irinotecan 65 130-nm albumin-bound paclitaxel 61 Paclitaxel 56 Cisplatin 56 Cetuximab 55 Cyclophosphamide 41 Albumin-Bound Paclitaxel 41 Radiotherapy 34 Docetaxel 31 durvalumab 30 Sorafenib 30 Taxes 27 Carboplatin 26 tislelizumab 22 fludarabine 21 Drug Therapy 21 Folfox protocol 20 atezolizumab 19 regorafenib 18 S 1 (combination) 18 Ipilimumab 17 sintilimab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03610711 2025-12-22

REACTION

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Active not recruiting

Gastrointestinal

Gastroesophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡